近肾、肾旁及肾上腹主动脉瘤腔内治疗应用增加且死亡风险随时间上升
该研究基于2011-2017年ACS NSQIP血管数据库分析18661例腹主动脉瘤修复患者,发现开放修复率下降而腔内修复率上升,复杂JPS AAA的EVAR应用增加;校正混杂因素后,JPS AAA接受EVAR的死亡风险随年份递增(OR 1.30),而开放修复无此趋势。
要点
- 复杂JPS AAA的EVAR应用增加,但校正后死亡风险逐年上升。
- 肾下AAA的EVAR与开放修复死亡风险随年份无显著变化。
- JPS AAA开放修复的死亡风险随年份无显著变化。
核心结论
- 腹主动脉瘤开放修复率下降、EVAR率上升,复杂JPS AAA的EVAR应用增加。
- 肾下AAA治疗的风险未受EVAR增加显著影响。
- JPS AAA接受EVAR的死亡风险随年份递增,而开放修复无此趋势。
研究设计与样本
- 回顾性队列研究,查询2011-2017年美国外科医师学会NSQIP血管靶向数据库。
- 共纳入18661例腹主动脉瘤修复患者,其中开放修复3941例(21.1%),EVAR 14720例(78.9%)。
- 对肾下及JPS AAA修复分别进行多变量逻辑回归分析。
主要发现
- 开放修复率从2011年29.5%降至2017年21.3%(P < 0.001),几何年均下降27.8%。
- EVAR率从70.5%升至78.7%(P < 0.001),几何年均增长11.6%。
- 肾下AAA:OAR或EVAR每增加一年,30天死亡、肾脏并发症或缺血性结肠炎风险无差异(P > 0.05)。
临床怎么用
- 复杂JPS AAA选择EVAR时需警惕随时间上升的死亡风险,应审慎评估。
- 肾下AAA的EVAR增加未伴随短期死亡或并发症风险显著变化。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Continued advances in endovascular technologies are resulting in fewer open abdominal aortic aneurysm (AAA) repairs. In addition, more complex juxtarenal, pararenal, and suprarenal (JPS) AAAs are being managed with various endovascular techniques. This study sought to evaluate the evolving trends in endovascular aneurysm repair (EVAR) of AAAs, hypothesizing increased rate of JPS AAA repair by EVAR. We also sought to evaluate the risk for morbidity and mortality for EVAR and open aneurysm repair (OAR) of JPS AAAs over time. METHODS: The 2011-2017 American College of Surgeons National Surgical Quality Improvement Program Procedure-Targeted Vascular database was queried for patients undergoing OAR or EVAR for AAAs. A multivariable logistic regression analysis was performed for both infrarenal and JPS AAA repairs. RESULTS: Of 18,661 patients who underwent AAA repair, 3,941 (21.1%) were OAR and 14,720 (78.9%) were EVAR. The rate of OAR decreased from 29.5% in 2011 to 21.3% in 2017 (P < 0.001) with a geometric-mean-annual decrease of 27.8%. The rate of EVAR increased from 70.5% to 78.7% during the same time period (P < 0.001) with a geometric-mean-annual increase of 11.6%. These trends remained true for both infrarenal and JPS AAAs. After adjusting for covariates, there was no difference in associated risk of 30-day mortality, renal complications, or ischemic colitis for either OAR or EVAR over each incremental year for infrarenal AAAs (P > 0.05). However, in patients undergoing EVAR for JPS AAAs, the associated risk of mortality increased with each incremental year (odds ratio [OR]: 1.30, confidence interval [CI]: 1.01-1.69, P = 0.039), whereas there was no difference in the risk of mortality for OAR of JPS AAAs with each incremental year (OR: 1.11, CI: 0.99-1.23, P = 0.067). CONCLUSIONS: The rate of OAR for AAA has decreased over the past seven years with an increase in EVAR, particularly for more complex JPS AAAs. The associated risk for morbidity and mortality for treatment of infrarenal AAAs was not significantly affected by this increased utility of EVAR. The associated risk of mortality for JPS AAAs treated by EVAR increased over time, whereas this trend for associated risk of mortality was not seen for OAR of JPS AAAs. These findings, especially the increased associated risk of mortality over time with EVAR for JPS AAAs, warrant careful prospective analysis.
引用
- Duong WQ, Fujitani RM, Grigorian A, et al. Evolving Utility of Endovascular Treatment of Juxtarenal, Pararenal, and Suprarenal Abdominal Aortic Aneurysms Associated With Increased Risk of Mortality Over Time. Ann Vasc Surg. 2020. PMID: 32889159. doi:10.1016/j.avsg.2020.08.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。